title: Characterization of bone marrow lymphoid infiltrates after immunochemotherapy for follicular lymphoma.
abstract: We studied the distribution of lymphoid cells in the bone marrow of 10 follicular lymphoma (FL) cases in complete response after immunochemotherapy but with nodular lymphoid infiltrates mimicking persistent lymphoma nodules. Immunohistochemical analysis showed that most of these cells displayed a T-cell phenotype with important proportions of regulatory T cells (CD3+/CD4+/FOXP3+) and mast cells. These populations were also present before treatment. Whereas no CD20+ cells were observed, immature B cells (CD79a+/terminal deoxynucleotidyl transferase+/CD20-) were detected. These cells were scarce before immunochemotherapy, suggesting that immunochemotherapy enabled their expansion. Fluorescence in situ hybridization and quantitative polymerase chain reaction failed to detect residual lymphoma cells in 5 cases with the t(14;18) translocation. Our study describes 2 important features in bone marrow in FL following immunochemotherapy. It is probable that the accumulation of regulatory T cells has some role in the control of FL. The expansion of nonmalignant B cells reflects the regeneration of B-cell lineage following immunochemotherapy.
authors.affiliation: INSERM, U.563, Physiopathology Center of Toulouse-Purpan, Paul-Sabatier University, and Department of Pathology, CHU Purpan, Toulouse, France.
authors.forename: Camille
authors.initials: C
authors.lastname: Laurent
authors.forename: Geisilene Rusno
authors.initials: GR
authors.lastname: de Paiva
authors.forename: Loic
authors.initials: L
authors.lastname: Ysebaert
authors.forename: Guy
authors.initials: G
authors.lastname: Laurent
authors.forename: Michel
authors.initials: M
authors.lastname: March
authors.forename: Georges
authors.initials: G
authors.lastname: Delsol
authors.forename: Pierre
authors.initials: P
authors.lastname: Brousset
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D001853:Bone Marrow / Q000473:pathology*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D017404:In Situ Hybridization, Fluorescence; D016131:Lymphocyte Subsets / Q000378:metabolism / Q000473:pathology*; D016246:Lymphocytes, Tumor-Infiltrating / Q000378:metabolism / Q000473:pathology*; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D012189:Retrospective Studies; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D014408:Biomarkers, Tumor; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone